Rathmell: A tough budget is an opportunity to make sure NCI is “doing what is best for the American public”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Next week, NCI will announce its plans for surviving on an austere budget given to it by Congress as fiscal year 2024 approaches the six-month mark.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
UCLA researchers have received a grant worth up to $7 million over five years from the National Institute of Allergy and Infectious Diseases to launch a first-in-human clinical trial evaluating whether drugs already used to treat autoimmune diseases can prevent or reverse immune checkpoint inhibitor-induced type 1 diabetes, a rare but often permanent complication of cancer immunotherapy.
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login